跳至主要内容
临床试验/NCT00790322
NCT00790322已完成3 期

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase III Clinical Study to Assess the Efficacy and Safety of SBG on Oral Mucositis in Head and Neck Cancer Patients Undergoing Radiation Therapy With or Without Chemotherapy

Biotec Pharmacon ASA1 个研究点 分布在 1 个国家目标入组 130 人开始时间: 2008年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
130
试验地点
1
主要终点
Compare the proportion of patients in the two arms who develop severe oral mucositis

研究概览

简要总结

The purpose of this study is to evaluate the efficacy and safety of SBG vs placebo on oral mucositis in head and neck cancer patients undergoing radiation therapy.

详细描述

The objective of the study is to evaluate the efficacy and safety of soluble beta-1,3/1,6-glucan (SBG) on oral mucositis compared to placebo in head and neck cancer patients undergoing radiation therapy with or without chemotherapy.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Active

Experimental

干预措施: SBG (Drug)

Placebo

Placebo Comparator

干预措施: Placebo (Other)

结局指标

主要结局

Compare the proportion of patients in the two arms who develop severe oral mucositis

时间窗: During radiation therapy

次要结局

未报告次要终点

研究者

发起方
Biotec Pharmacon ASA
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验